Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Cartesian Therapeutics

Clinical trials sponsored by Cartesian Therapeutics, explained in plain language.

Cartesian Therapeutics RNAC NASDAQ

A clinical-stage biotech developing RNA cell therapies for autoimmune diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 3 Not yet finished but already full! 2 Terminated 1

Experimental CAR t therapy targets tough myeloma cases

Disease control Terminated

This early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 parti…

Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 07:59 UTC